Literature DB >> 1701811

Biologic effects of interferons.

I Gresser1.   

Abstract

If one were to review articles on IFN published between 1957 and 1967 it would become apparent that virtually none of the tenets held then are still valid today. Whereas IFN was long considered to be a specific antiviral substance without any effect on normal cellular metabolism, we accept today that it affects normal cell division and many specialized cellular functions. In this respect it is not unique; IFN is a prototype of a family of similar substances now called cytokines that all appear to function as regulatory molecules. It was held that the production of IFN constituted a specific response to a viral infection. Today we believe that IFN is an integral part of a cytokine network and that they and other cytokines may be produced constitutively at low levels. These substances exert multiple effects on virtually all cells. They play an important role in host defense against viral and parasitic infections, and in the resistance to experimental tumors. IFN can be shown to exert effects on the immune system and on lymphocyte circulation. Lastly, because of the multiplicity of their biologic effects, they may even contribute to the pathogenesis of certain diseases. Thus, when large amounts of IFN are administered or induced in newborn mice they can cause liver, kidney, and pulmonary disease. The field of IFN and cytokine research continues to expand and there is an increasing number of therapeutic applications. Twenty years from now, scientists and clinicians may be surprised that we understood so little of how IFN act and how inadequately we used them to treat disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701811     DOI: 10.1111/1523-1747.ep12874776

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  27 in total

1.  Distinct roles for the NF-kappa B RelA subunit during antiviral innate immune responses.

Authors:  Suresh H Basagoudanavar; Roshan J Thapa; Shoko Nogusa; Junmei Wang; Amer A Beg; Siddharth Balachandran
Journal:  J Virol       Date:  2011-01-05       Impact factor: 5.103

Review 2.  Constitutive type I interferon modulates homeostatic balance through tonic signaling.

Authors:  Daniel J Gough; Nicole L Messina; Christopher J P Clarke; Ricky W Johnstone; David E Levy
Journal:  Immunity       Date:  2012-02-24       Impact factor: 31.745

3.  Interferon alpha concentrations in blood and peritoneal fluid during treatment for hepatitis C.

Authors:  C Smirne; R Minisini; M E Burlone; E Ceriani; F Corlianò; G Occhino; M Pirisi
Journal:  Perit Dial Int       Date:  2012 Nov-Dec       Impact factor: 1.756

4.  Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome.

Authors:  Makoto Inoue; Kristi L Williams; Timothy Oliver; Peter Vandenabeele; Jayant V Rajan; Edward A Miao; Mari L Shinohara
Journal:  Sci Signal       Date:  2012-05-22       Impact factor: 8.192

Review 5.  Interferons and their stimulated genes in the tumor microenvironment.

Authors:  Hyeonjoo Cheon; Ernest C Borden; George R Stark
Journal:  Semin Oncol       Date:  2014-02-14       Impact factor: 4.929

6.  Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide.

Authors:  S A Buechner; M Wernli; T Harr; S Hahn; P Itin; P Erb
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

Review 7.  Tumor-suppressor genes: news about the interferon connection.

Authors:  P Lengyel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

8.  Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis.

Authors:  Vanessa S Cull; Emmalene J Bartlett; Cassandra M James
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

9.  Inflammation activates the interferon signaling pathways in taste bud cells.

Authors:  Hong Wang; Minliang Zhou; Joseph Brand; Liquan Huang
Journal:  J Neurosci       Date:  2007-10-03       Impact factor: 6.167

Review 10.  Emerging strategies for cancer immunoprevention.

Authors:  J C Roeser; S D Leach; F McAllister
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.